Development asset linked to Dong Wang in public FDA and regional records.
pharma · Androgenetic Alopecia · Acute Myocardial Infarction
Dong Wang
Dong Wang drug portfolio — 13 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 8
- Drugs
- 13
- Patents
- 0
Dong Wang pipeline
Portfolio lens on 13 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Dong Wang drug portfolio — 13 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
amlodipine
Cardiovascular system (C09)Cardiovascular system (C09) compound in Dong Wang's portfolio. Mechanism: Voltage-gated L-type calcium channel blocker.
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
US regulatory status: approved. Molecular target: Acetylcholinesterase.
- Target
- Acetylcholinesterase
- Mechanism
- Acetylcholinesterase inhibitor
-
Development asset linked to Dong Wang in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
Development asset linked to Dong Wang in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Farnesyl pyrophosphate synthase.
- Target
- Farnesyl pyrophosphate synthase
- Mechanism
- Farnesyl diphosphate synthase inhibitor
-
rivastigmine
Nervous system (N06)US regulatory status: approved. Molecular target: Cholinesterases; ACHE & BCHE.
- Target
- Cholinesterases; ACHE & BCHE
- Mechanism
- Cholinesterases; ACHE & BCHE inhibitor
-
US regulatory status: approved. Molecular target: Cholinesterases; ACHE & BCHE.
- Target
- Cholinesterases; ACHE & BCHE
- Mechanism
- Cholinesterases; ACHE & BCHE inhibitor
-
Development asset linked to Dong Wang in public FDA and regional records.
-
telmisartan
Cardiovascular system (C09)US regulatory status: approved. Molecular target: Type-1 angiotensin II receptor.
- Target
- Type-1 angiotensin II receptor
- Mechanism
- Type-1 angiotensin II receptor antagonist
-
Development asset linked to Dong Wang in public FDA and regional records.